中文VIENTIANE, VIENTIANE, LAO PDR, June 28, 2023 Lao Food and Drug Administration came to Big Bear Pharma to inspect and guide the traditional medicine factory.
The investor team of Big Bear Pharmaceuticals went to Laos to investigate the investment environment in 2021, and formally invested in the construction of production facilities in 2021. After nearly a year of engineering construction and improvement, the pharmaceutical factory area finally ushered in the first inspection by the Lao Food and Drug Administration.
The inspection by the Lao Food and Drug Administration provided constructive guidance for BigBear pharma to improve the production standards of traditional medicine and establish production norms in the next step.
The CEO of Big Bear Pharma said: "It is a great pleasure to welcome the inspection by the Ministry of Health. This inspection is a key step for the company. With the support of investors and all employees, we will continue to build and improve the relevant facilities and standards for the production of traditional medicine. This It is a very different path from before, but we will always insist on innovation and exploration."
About BigBear pharmaceutical. (www.BigBearpharma.com)
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of cancer patients by providing them with more choices, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.